ScholarIQanswers from OpenAlex & ORCID
Axel Haupt
ResearcherPublications, citations & collaboration network
Axel Haupt is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Axel Haupt have?
ScholarIQindexed works
Axel Haupt has 186 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Axel Haupt have?
ScholarIQcitation count
Axel Haupt has 11,031 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Axel Haupt?
ScholarIQh-index
Axel Haupt has an h-index of 47 in OpenAlex.
What is the i10-index of Axel Haupt?
ScholarIQi10-index
Axel Haupt has an i10-index of 82 in OpenAlex.
What is the ORCID of Axel Haupt?
ScholarIQorcid
The ORCID for Axel Haupt is on the source record.
What is the OpenAlex record for Axel Haupt?
ScholarIQopenalex
The OpenAlex for Axel Haupt is on the source record.
What are the most-cited papers on Axel Haupt?
ScholarIQmost cited works
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Miličević, Mark L. Hartman
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Cynthia Behling, Oscar W. Cummings, Yuanyuan Tang, Bram Brouwers, Deborah A. Robins, Amir Nikooie, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E. Gimeno, Zvonko Miličević, Deborah A. Robins, Axel Haupt
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, Julio Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, Kieren J. Mather, Axel Haupt, Deborah A. Robins, Edward Pratt, Christof Kazda, Маниге Кониг